Related Articles
Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide
Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner
Combinations of tumor-specific CD8+ CTLs and anti-CD25 mAb provide improved immunotherapy
CCL11 increases the proportion of CD4+CD25+Foxp3+ Treg cells and the production of IL‑2 and TGF‑β by CD4+ T cells via the STAT5 signaling pathway
Simultaneously increased expression of glucocorticoid‑induced tumor necrosis factor receptor and its ligand contributes to increased interleukin‑5/13‑producing group 2 innate lymphocytes in murine asthma